BofA raised the firm’s price target on Cellebrite to $9 from $8 and keeps a Neutral rating on the shares. While the firm awaits more stable growth and profitability trends, it raised its price target on Cellebrite shares given the increase in sector multiples.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CLBT: